Samsara BioCapital’s Chinook Therapeutics, Inc. Common Stock KDNY Stock Holding History

Samsara BioCapital’s Portfolio KDNY Stock Details KDNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-5,161,888	Closed	-$198M	–	48
2023 Q2	$198M	Hold	5,161,888	–	–	34.81%	1
2023 Q1	$119M	Hold	5,161,888	–	–	24.7%	1
2022 Q4	$135M	Hold	5,161,888	–	–	29.11%	1
2022 Q3	$101M	Hold	5,161,888	–	–	23.66%	1
2022 Q2	$90.3M	Buy	5,161,888 +570,000	+12%	+$8.95M	24.07%	1
2022 Q1	$75.1M	Hold	4,591,888	–	–	18.91%	1
2021 Q4	$74.9M	Buy	4,591,888 +1,215,000	+36%	+$17.3M	14.53%	2
2021 Q3	$43.1M	Buy	3,376,888 +208,500	+7%	+$2.74M	6.76%	3
2021 Q2	$44.7M	Hold	3,168,388	–	–	5.52%	3
2021 Q1	$49.2M	Hold	3,168,388	–	–	9.08%	2
2020 Q4	$50.3K	Buy	+3,168,388	New	+$47.8M	5.05%	3

Samsara BioCapital's KDNY Position: Q3 2023 in Review

Samsara BioCapital sold out of Chinook Therapeutics, Inc. Common Stock (KDNY) in Q3 2023, closing a stake of 5,161,888 shares — an estimated $198M sold.

Samsara BioCapital first reported a position in KDNY in Q4 2020 and held it in 11 quarters. The position peaked at $198M in Q2 2023. 2 funds tracked by Wall St. Rank hold KDNY as of Q3 2023.

Samsara BioCapital reported no remaining Chinook Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Samsara BioCapital sold 5,161,888 Chinook Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $198M.
Samsara BioCapital first reported a position in Chinook Therapeutics, Inc. Common Stock in Q4 2020 and held it in 11 quarters.
Samsara BioCapital's Chinook Therapeutics, Inc. Common Stock position peaked at $198M in Q2 2023.
2 funds tracked by Wall St. Rank held Chinook Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Samsara BioCapital's 13F filing for Q3 2023, filed 14 Nov 2023.